Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John York

Vascular Surgery Greenville, SC Medical Doctor

NPI 1700828746 CMS profile 304522

200 Patewood Dr Ste C300, Greenville, SC 29615

Open in the dashboard

General payments

$41,981

428 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John York of Greenville, SC is reported in the CMS Open Payments database as having received $41,981 across 428 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,604 58
2024 General $3,158 48
2023 General $3,215 55
2022 General $9,568 52
2021 General $10,772 74
2020 General $8,042 69
2019 General $3,622 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John York
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to John York were reported at $3,604. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year John York Vascular Surgery median Middle half National median
2019 $3,622 $796 $226–$2,363 $163
2020 $8,042 $348 $118–$1,110 $114
2021 $10,772 $471 $158–$1,421 $132
2022 $9,568 $725 $222–$2,183 $149
2023 $3,215 $836 $257–$2,440 $160
2024 $3,158 $909 $252–$2,619 $164
2025 $3,604 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Shockwave Medical, Inc $18,186 38 payments
  2. W. L. Gore & Associates, Inc. $10,918 109 payments
  3. Cook Medical LLC $4,932 128 payments
  4. Philips Electronics North America Corporation $2,354 38 payments
  5. Penumbra, Inc. $1,328 15 payments
  6. Stryker Corporation $877 5 payments
  7. Surmodics, Inc. $662 22 payments
  8. Endologix, Inc. $552 5 payments
  9. Cagent Vascular LLC $353 8 payments
  10. Silk Road Medical, Inc. $341 6 payments
  11. Other $1,478 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $24,216 418 payments
  2. Consulting Fee $9,000 3 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $6,500 3 payments
  4. Honoraria $1,500 1 payment
  5. Travel and Lodging $765 3 payments
Products named General payments · program years 2019–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $7,628 16 payments
  2. Vascular Lithotripsy Lithoplasty $6,589 9 payments
  3. Vascular Lithotripsy Lithoplasty $3,539 6 payments
  4. Conformable TAG Thoracic Endoprosthesis $2,187 23 payments
  5. GORE TAG Conformable Thoracic Endoprosthesis $1,804 17 payments
  6. IGT D Peripheral $1,750 16 payments
  7. GORE VIABAHN VBX Balloon Expandable Endo $1,657 15 payments
  8. EXCLUDER Conformable AAA Endoprosthesis with Active Control $1,338 14 payments
  9. Indigo System $994 10 payments
  10. GORE VIABAHN Endoprosthesis with Heparin $935 7 payments
  11. Other $15,915 347 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

75

Median for Vascular Surgery: 122

Drug cost

$14,975

Median for Vascular Surgery: $14,135

Branded share of claims

73.3%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 21 $14,572
Clopidogrel Clopidogrel Bisulfate Brand 34 $370
Tramadol Hcl Generic 20 $33

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$68,342

Medicare's payments for the services billed

Medicare patients

312

Average age 74

Services billed

660

133 women, 179 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 50%
Chronic kidney disease 47%
Diabetes 46%
Depression 31%
Heart failure 29%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

428 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record